|Attorney Paul Skiermont says Court May Affirm Gene Patent|
|August 2, 2012 7:59 am|
A federal appeals court in Washington, D.C., is reviewing its ruling of last year that a Utah company can be the exclusive U.S. provider of genetic screenings for breast cancer and ovarian cancer. The Federal Circuit previously upheld Myriad Genetics' patents on two genes that can signal if a woman faces greater risk of developing the diseases. The U.S. Supreme Court ordered the Federal Circuit to reconsider the case in light of its ruling in a different case that tightened rules on medical-testing patents. "The Myriad case illustrates the enormous role the federal judiciary will play in defining the direction of the life sciences market," says Paul Skiermont of Dallas' Skiermont Puckett. "This case could resolve the multibillion-dollar question of whether a potential cure for cancer from DNA sequencing and extraction is a patentable invention, or a patent-ineligible discovery of a law of nature." For more information, contact Barry Pound at 800-559-4534 or firstname.lastname@example.org.
Send this page to a friend